top of page

Latest News

May 9, 2023

FDA extends approval of Dapagliflozin

Based on the positive results from the DELIVER Phase III trial, the FDA has extended approval of dapagliflozin to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure (HF) visits in adults with HF.

FDA extends approval of Dapagliflozin

Dec 24, 2022

AHA includes DELIVER in top advances in cardiovascular disease in 2022

The American Heart Association recognizes DELIVER and the SGLT2 meta-analysis in the top cardiovascular research of 2022

AHA includes DELIVER in top advances in cardiovascular disease in 2022

Dec 15, 2022

DELIVER featured on Cardiology Today

DELIVER featured in Cardiology Today

DELIVER featured on Cardiology Today

Nov 4, 2022

DELIVER at the AHA

DELIVER presentations at AHA

DELIVER at the  AHA

Nov 3, 2022

DELIVER at the ASN

DELIVER at the ASN

Oct 4, 2022

DELIVER at the HFSA

DELIVER presentations at HFSA

DELIVER at the HFSA
bottom of page